PUBLISHER: The Business Research Company | PRODUCT CODE: 2106465
PUBLISHER: The Business Research Company | PRODUCT CODE: 2106465
Long-Acting Injectables (LAIs) Global Market Report 2026
Long-acting injectables (LAIs) are medications formulated to provide a gradual and sustained release of active ingredients into the body over an extended duration following a single injection. This drug delivery approach maintains consistent therapeutic concentrations in the bloodstream for several weeks or months, thereby decreasing the requirement for frequent administration compared with conventional oral medications or short-duration injectable therapies.
The primary product types of long-acting injectables (LAIs) include antipsychotic long-acting injectables, hormonal long-acting injectables, antiviral long-acting injectables, pain management long-acting injectables, and other product types. Antipsychotic long-acting injectables refer to extended-release injectable formulations designed to provide sustained therapeutic effects and improve treatment adherence. These products are based on technologies including microsphere-based formulations, polymer-based depot systems, nano-formulations, liposomal delivery systems, and in-situ forming depots, and are administered through intramuscular, subcutaneous, and other routes of administration. The key applications include schizophrenia, bipolar disorder, human immunodeficiency virus treatment, hormonal disorders, diabetes management, and oncology supportive care, while the end users include hospitals, specialty clinics, ambulatory surgical centers, homecare settings, and specialty pharmacies.
Tariffs are influencing the long-acting injectables (LAIs) market by increasing the cost of imported active pharmaceutical ingredients, specialized polymers, drug delivery devices, and sterile manufacturing equipment required for sustained-release formulations. This is disrupting supply chains and increasing production costs, particularly affecting nano-formulations and polymer-based depot systems that rely on advanced global sourcing networks. Regions such as North America and Europe, which depend on imports from Asia-Pacific manufacturing hubs, are experiencing delays in production scaling and commercialization. However, tariffs are also encouraging localization of pharmaceutical manufacturing, strengthening regional supply chains, and accelerating investment in domestic production capabilities, which may improve long-term supply security and cost optimization.
The long-acting injectables (LAIs) market size has grown rapidly in recent years. It will grow from $13.31 billion in 2025 to $15.01 billion in 2026 at a compound annual growth rate (CAGR) of 12.7%. The growth in the historic period can be attributed to rising incidence of schizophrenia and bipolar disorder, increasing need for improved medication adherence systems, early-stage development of depot injection technologies, growing application of hormonal injectable contraceptives, and limited availability of long-acting sustained-release drug delivery solutions.
The long-acting injectables (LAIs) market size is expected to see rapid growth in the next few years. It will grow to $24.45 billion in 2030 at a compound annual growth rate (CAGR) of 13.0%. The growth in the forecast period is driven by advancements in nano-based and polymer-based drug delivery systems, rising approvals of long-duration antiviral therapies, increasing adoption of precision medicine strategies, expansion of outpatient and home-based care models, and growing investments in extended-release injectable drug development pipelines. Key trends in the forecast period include increased use of long-acting injectable treatments for chronic psychiatric disorders, rising adoption of depot formulations to enhance patient adherence and reduce dosing frequency, development of advanced polymeric and nanotechnology-based sustained-release drug systems, expanding clinical use of long-acting antivirals in infectious disease management, and greater integration of long-acting injectables into outpatient and specialty care settings.
The increasing burden of schizophrenia is expected to propel the growth of the long-acting injectables (LAIs) market going forward. Schizophrenia is a chronic mental health disorder that affects a person's thinking, emotions, and behavior, often causing hallucinations, delusions, and disorganized thinking. The rising burden of schizophrenia is attributed to improved mental health awareness, which leads to more individuals recognizing symptoms and seeking diagnosis. Long-acting injectables (LAIs) aid in the management of schizophrenia by ensuring consistent medication delivery over time, thereby improving treatment adherence, reducing relapse risk, and supporting better long-term symptom control. For instance, in January 2026, according to WebMD LLC, a US-based online digital health platform, schizophrenia imposed an economic burden of nearly $367 billion in the United States in 2024, affecting about 3.1 million adults. Therefore, the increasing burden of schizophrenia is driving the growth of the long-acting injectables (LAIs) market.
Key companies operating in the long-acting injectables (LAIs) market are focusing on developing innovative solutions, such as advanced sustained-release depot formulation platforms, to enable longer dosing intervals, improve patient adherence, and enhance therapeutic consistency. Advanced sustained-release depot formulation platforms are drug delivery systems that store medication in a long-acting injectable form at the injection site and release it slowly and steadily into the body over an extended period to maintain consistent therapeutic levels. For example, in November 2025, Lupin Limited, an India-based pharmaceutical company, launched risperidone long-acting injectable under its proprietary precision sphere platform, designed to provide extended drug release and improved dosing convenience with CGT exclusivity in the United States. The platform incorporates advanced polymer-based delivery technology that enables sustained release of the active ingredient over an extended duration, supports better patient compliance, and reduces relapse risk by maintaining stable therapeutic levels, marking a strategic advancement in long-acting injectable therapies for neuropsychiatric conditions.
In November 2023, Teva Pharmaceutical Industries Ltd., an Israel-based biopharmaceutical company, entered into a collaboration with Royalty Pharma to accelerate development of its olanzapine long-acting injectable (LAI) program (TEV-749) for the treatment of schizophrenia. This partnership is designed to support late-stage clinical development of the LAI formulation through non-dilutive funding in exchange for future royalty rights, thereby reducing financial exposure and accelerating time-to-market for the long-acting injectable therapy aimed at improving patient adherence through sustained drug release. Royalty Pharma Plc is a US-based biopharmaceutical royalty and investment company focused on funding innovative drug development programs in exchange for future royalty-based returns.
Major companies operating in the long-acting injectables (LAIs) market are Johnson And Johnson, Roche Holding AG, Pfizer Inc., Merck & Co. Inc., AbbVie Inc., AstraZeneca plc, Sanofi S.A., Novartis AG, Novo Nordisk A/S, GSK plc, Eli Lilly and Company, Bayer AG, Takeda Pharmaceutical Company Limited, Amgen Inc., Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co Ltd., Shionogi And Co Ltd., Dr. Reddy's Laboratories Ltd., ViiV Healthcare, H. Lundbeck A/S, Lupin Limited, Amneal Pharmaceuticals Inc., Alkermes plc, Syngene International Limited
North America was the dominant region in the long-acting injectables (LAIs) market in 2025. Asia-Pacific is expected to be the rapidly expanding region in the forecast period. The regions covered in long-acting injectables (LAIs) report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the long-acting injectables (LAIs) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The long-acting injectables (LAIs) market consists of sales of paliperidone palmitate, risperidone microspheres, aripiprazole monohydrate, olanzapine pamoate, and naltrexone extended-release injectable. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
The long-acting injectables (LAIs) market research report is one of a series of new reports from The Business Research Company that provides long-acting injectables (LAIs) market statistics, including long-acting injectables (LAIs) industry global market size, regional shares, competitors with a long-acting injectables (LAIs) market share, detailed long-acting injectables (LAIs) market segments, market trends and opportunities, and any further data you may need to thrive in the long-acting injectables (LAIs) industry. This long-acting injectables (LAIs) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Long-Acting Injectables (LAIs) Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses long-acting injectables (lais) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for long-acting injectables (lais) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The long-acting injectables (lais) market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Scope
- Markets Covered:1) By Product Type: Antipsychotic Long Acting Injectables; Hormonal Long Acting Injectables; Antiviral Long Acting Injectables; Pain Management Long Acting Injectables; Other Product Types
- 2) By Technology: Microsphere Based Formulations; Polymer Based Depot Systems; Nano Formulations; Liposomal Delivery Systems; In Situ Forming Depots
- 3) By Route Of Administration: Intramuscular; Subcutaneous; Other Routes Of Administration
- 4) By Application: Schizophrenia; Bipolar Disorder; Human Immunodeficiency Virus Treatment; Hormonal Disorders; Diabetes Management; Oncology Supportive Care
- 5) By End User: Hospitals; Specialty Clinics; Ambulatory Surgical Centers; Homecare Settings; Specialty Pharmacies
- Subsegments:
- 1) By Antipsychotic Long Acting Injectables: Risperidone Long Acting Injection; Paliperidone Palmitate Injection; Aripiprazole Extended Release Injection; Olanzapine Long Acting Injection; Fluphenazine Decanoate Injection; Haloperidol Decanoate Injection
- 2) By Hormonal Long Acting Injectables: Depot Medroxyprogesterone Acetate Injection; Leuprolide Acetate Injection; Goserelin Acetate Implant Injection; Norethisterone Enanthate Injection; Estradiol Valerate Injection
- 3) By Antiviral Long Acting Injectables: Cabotegravir Extended Release Injection; Rilpivirine Long Acting Injection; Lenacapavir Subcutaneous Injection; Interferon Alpha Long Acting Injection
- 4) By Pain Management Long Acting Injectables: Bupivacaine Extended Release Injection; Morphine Depot Injection; Buprenorphine Extended Release Injection; Fentanyl Depot Injection; Methadone Long Acting Injection
- 5) By Other Product Types: Oncology Long Acting Injectables; Anti Infective Long Acting Injectables; Immunotherapy Long Acting Injectables; Vaccination Depot Formulations; Metabolic Disorder Long Acting Injectables
- Companies Mentioned: Johnson And Johnson; Roche Holding AG; Pfizer Inc.; Merck & Co. Inc.; AbbVie Inc.; AstraZeneca plc; Sanofi S.A.; Novartis AG; Novo Nordisk A/S; GSK plc; Eli Lilly and Company; Bayer AG; Takeda Pharmaceutical Company Limited; Amgen Inc.; Gilead Sciences Inc.; Teva Pharmaceutical Industries Ltd.; Otsuka Pharmaceutical Co Ltd.; Shionogi And Co Ltd.; Dr. Reddy's Laboratories Ltd.; ViiV Healthcare; H. Lundbeck A/S; Lupin Limited; Amneal Pharmaceuticals Inc.; Alkermes plc; Syngene International Limited
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time Series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery Format: Word, PDF or Interactive Report
- + Excel Dashboard
- Added Benefits
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.
Table of Contents
1. Executive Summary
- 1.1. Key Market Insights (2020-2035)
- 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
- 1.3. Major Factors Driving the Market
- 1.4. Top Three Trends Shaping the Market
2. Long-Acting Injectables (LAIs) Market Characteristics
- 2.1. Market Definition & Scope
- 2.2. Market Segmentations
- 2.3. Overview of Key Products and Services
- 2.4. Global Long-Acting Injectables (LAIs) Market Attractiveness Scoring And Analysis
- 2.4.1. Overview of Market Attractiveness Framework
- 2.4.2. Quantitative Scoring Methodology
- 2.4.3. Factor-Wise Evaluation
- Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
- 2.4.4. Market Attractiveness Scoring and Interpretation
- 2.4.5. Strategic Implications and Recommendations
3. Long-Acting Injectables (LAIs) Market Supply Chain Analysis
- 3.1. Overview of the Supply Chain and Ecosystem
- 3.2. List Of Key Raw Materials, Resources & Suppliers
- 3.3. List Of Major Distributors and Channel Partners
- 3.4. List Of Major End Users
4. Global Long-Acting Injectables (LAIs) Market Trends And Strategies
- 4.1. Key Technologies & Future Trends
- 4.1.1 Biotechnology, Genomics & Precision Medicine
- 4.1.2 Digitalization, Cloud, Big Data & Cybersecurity
- 4.1.3 Industry 4.0 & Intelligent Manufacturing
- 4.1.4 Artificial Intelligence & Autonomous Intelligence
- 4.1.5 Internet Of Things (IoT), Smart Infrastructure & Connected Ecosystems
- 4.2. Major Trends
- 4.2.1 Rising Adoption Of Long Acting Injectable Therapies For Chronic Psychiatric Disorder Management
- 4.2.2 Increasing Use Of Depot Formulations To Improve Patient Adherence And Reduce Dosing Frequency
- 4.2.3 Growing Development Of Advanced Polymer And Nano Based Drug Delivery Systems For Sustained Release
- 4.2.4 Expanding Clinical Adoption Of Long Acting Antivirals For Infectious Disease Management
- 4.2.5 Increasing Integration Of Long Acting Injectables In Outpatient And Specialty Clinic Treatment Models
5. Long-Acting Injectables (LAIs) Market Analysis Of End Use Industries
- 5.1 Hospitals
- 5.2 Specialty Clinics
- 5.3 Ambulatory Surgical Centers
- 5.4 Homecare Settings
- 5.5 Specialty Pharmacies
6. Long-Acting Injectables (LAIs) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market
7. Global Long-Acting Injectables (LAIs) Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis
- 7.1. Global Long-Acting Injectables (LAIs) PESTEL Analysis (Political, Economical, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 7.2. Global Long-Acting Injectables (LAIs) Market Size, Comparisons And Growth Rate Analysis
- 7.3. Global Long-Acting Injectables (LAIs) Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
- 7.4. Global Long-Acting Injectables (LAIs) Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)
8. Global Long-Acting Injectables (LAIs) Total Addressable Market (TAM) Analysis for the Market
- 8.1. Definition and Scope of Total Addressable Market (TAM)
- 8.2. Methodology and Assumptions
- 8.3. Global Total Addressable Market (TAM) Estimation
- 8.4. TAM vs. Current Market Size Analysis
- 8.5. Strategic Insights and Growth Opportunities from TAM Analysis
9. Long-Acting Injectables (LAIs) Market Segmentation
- 9.1. Global Long-Acting Injectables (LAIs) Market, Segmentation By Product Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
- Antipsychotic Long Acting Injectables, Hormonal Long Acting Injectables, Antiviral Long Acting Injectables, Pain Management Long Acting Injectables, Other Product Types
- 9.2. Global Long-Acting Injectables (LAIs) Market, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
- Microsphere Based Formulations, Polymer Based Depot Systems, Nano Formulations, Liposomal Delivery Systems, In Situ Forming Depots
- 9.3. Global Long-Acting Injectables (LAIs) Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
- Intramuscular, Subcutaneous, Other Routes Of Administration
- 9.4. Global Long-Acting Injectables (LAIs) Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
- Schizophrenia, Bipolar Disorder, Human Immunodeficiency Virus Treatment, Hormonal Disorders, Diabetes Management, Oncology Supportive Care
- 9.5. Global Long-Acting Injectables (LAIs) Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
- Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Homecare Settings, Specialty Pharmacies
- 9.6. Global Long-Acting Injectables (LAIs) Market, Sub-Segmentation Of Antipsychotic Long Acting Injectables, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
- Risperidone Long Acting Injection, Paliperidone Palmitate Injection, Aripiprazole Extended Release Injection, Olanzapine Long Acting Injection, Fluphenazine Decanoate Injection, Haloperidol Decanoate Injection
- 9.7. Global Long-Acting Injectables (LAIs) Market, Sub-Segmentation Of Hormonal Long Acting Injectables, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
- Depot Medroxyprogesterone Acetate Injection, Leuprolide Acetate Injection, Goserelin Acetate Implant Injection, Norethisterone Enanthate Injection, Estradiol Valerate Injection
- 9.8. Global Long-Acting Injectables (LAIs) Market, Sub-Segmentation Of Antiviral Long Acting Injectables, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
- Cabotegravir Extended Release Injection, Rilpivirine Long Acting Injection, Lenacapavir Subcutaneous Injection, Interferon Alpha Long Acting Injection
- 9.9. Global Long-Acting Injectables (LAIs) Market, Sub-Segmentation Of Pain Management Long Acting Injectables, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
- Bupivacaine Extended Release Injection, Morphine Depot Injection, Buprenorphine Extended Release Injection, Fentanyl Depot Injection, Methadone Long Acting Injection
- 9.10. Global Long-Acting Injectables (LAIs) Market, Sub-Segmentation Of Other Product Types, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
- Oncology Long Acting Injectables, Anti Infective Long Acting Injectables, Immunotherapy Long Acting Injectables, Vaccination Depot Formulations, Metabolic Disorder Long Acting Injectables
10. Long-Acting Injectables (LAIs) Market Regional And Country Analysis
- 10.1. Global Long-Acting Injectables (LAIs) Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
- 10.2. Global Long-Acting Injectables (LAIs) Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
11. Asia-Pacific Long-Acting Injectables (LAIs) Market
- 11.1. Asia-Pacific Long-Acting Injectables (LAIs) Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 11.2. Asia-Pacific Long-Acting Injectables (LAIs) Market, Segmentation By Product Type, Segmentation By Technology, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
12. China Long-Acting Injectables (LAIs) Market
- 12.1. China Long-Acting Injectables (LAIs) Market Overview
- Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 12.2. China Long-Acting Injectables (LAIs) Market, Segmentation By Product Type, Segmentation By Technology, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
13. India Long-Acting Injectables (LAIs) Market
- 13.1. India Long-Acting Injectables (LAIs) Market, Segmentation By Product Type, Segmentation By Technology, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
14. Japan Long-Acting Injectables (LAIs) Market
- 14.1. Japan Long-Acting Injectables (LAIs) Market Overview
- Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 14.2. Japan Long-Acting Injectables (LAIs) Market, Segmentation By Product Type, Segmentation By Technology, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
15. Australia Long-Acting Injectables (LAIs) Market
- 15.1. Australia Long-Acting Injectables (LAIs) Market, Segmentation By Product Type, Segmentation By Technology, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
16. Indonesia Long-Acting Injectables (LAIs) Market
- 16.1. Indonesia Long-Acting Injectables (LAIs) Market, Segmentation By Product Type, Segmentation By Technology, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
17. South Korea Long-Acting Injectables (LAIs) Market
- 17.1. South Korea Long-Acting Injectables (LAIs) Market Overview
- Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 17.2. South Korea Long-Acting Injectables (LAIs) Market, Segmentation By Product Type, Segmentation By Technology, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
18. Taiwan Long-Acting Injectables (LAIs) Market
- 18.1. Taiwan Long-Acting Injectables (LAIs) Market Overview
- Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 18.2. Taiwan Long-Acting Injectables (LAIs) Market, Segmentation By Product Type, Segmentation By Technology, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
19. South East Asia Long-Acting Injectables (LAIs) Market
- 19.1. South East Asia Long-Acting Injectables (LAIs) Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 19.2. South East Asia Long-Acting Injectables (LAIs) Market, Segmentation By Product Type, Segmentation By Technology, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
20. Western Europe Long-Acting Injectables (LAIs) Market
- 20.1. Western Europe Long-Acting Injectables (LAIs) Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 20.2. Western Europe Long-Acting Injectables (LAIs) Market, Segmentation By Product Type, Segmentation By Technology, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
21. UK Long-Acting Injectables (LAIs) Market
- 21.1. UK Long-Acting Injectables (LAIs) Market, Segmentation By Product Type, Segmentation By Technology, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
22. Germany Long-Acting Injectables (LAIs) Market
- 22.1. Germany Long-Acting Injectables (LAIs) Market, Segmentation By Product Type, Segmentation By Technology, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
23. France Long-Acting Injectables (LAIs) Market
- 23.1. France Long-Acting Injectables (LAIs) Market, Segmentation By Product Type, Segmentation By Technology, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
24. Italy Long-Acting Injectables (LAIs) Market
- 24.1. Italy Long-Acting Injectables (LAIs) Market, Segmentation By Product Type, Segmentation By Technology, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
25. Spain Long-Acting Injectables (LAIs) Market
- 25.1. Spain Long-Acting Injectables (LAIs) Market, Segmentation By Product Type, Segmentation By Technology, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
26. Eastern Europe Long-Acting Injectables (LAIs) Market
- 26.1. Eastern Europe Long-Acting Injectables (LAIs) Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 26.2. Eastern Europe Long-Acting Injectables (LAIs) Market, Segmentation By Product Type, Segmentation By Technology, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
27. Russia Long-Acting Injectables (LAIs) Market
- 27.1. Russia Long-Acting Injectables (LAIs) Market, Segmentation By Product Type, Segmentation By Technology, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
28. North America Long-Acting Injectables (LAIs) Market
- 28.1. North America Long-Acting Injectables (LAIs) Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 28.2. North America Long-Acting Injectables (LAIs) Market, Segmentation By Product Type, Segmentation By Technology, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
29. USA Long-Acting Injectables (LAIs) Market
- 29.1. USA Long-Acting Injectables (LAIs) Market Overview
- Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 29.2. USA Long-Acting Injectables (LAIs) Market, Segmentation By Product Type, Segmentation By Technology, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
30. Canada Long-Acting Injectables (LAIs) Market
- 30.1. Canada Long-Acting Injectables (LAIs) Market Overview
- Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 30.2. Canada Long-Acting Injectables (LAIs) Market, Segmentation By Product Type, Segmentation By Technology, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
31. South America Long-Acting Injectables (LAIs) Market
- 31.1. South America Long-Acting Injectables (LAIs) Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 31.2. South America Long-Acting Injectables (LAIs) Market, Segmentation By Product Type, Segmentation By Technology, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
32. Brazil Long-Acting Injectables (LAIs) Market
- 32.1. Brazil Long-Acting Injectables (LAIs) Market, Segmentation By Product Type, Segmentation By Technology, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
33. Middle East Long-Acting Injectables (LAIs) Market
- 33.1. Middle East Long-Acting Injectables (LAIs) Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 33.2. Middle East Long-Acting Injectables (LAIs) Market, Segmentation By Product Type, Segmentation By Technology, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
34. Africa Long-Acting Injectables (LAIs) Market
- 34.1. Africa Long-Acting Injectables (LAIs) Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 34.2. Africa Long-Acting Injectables (LAIs) Market, Segmentation By Product Type, Segmentation By Technology, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
35. Long-Acting Injectables (LAIs) Market Regulatory and Investment Landscape
36. Long-Acting Injectables (LAIs) Market Competitive Landscape And Company Profiles
- 36.1. Long-Acting Injectables (LAIs) Market Competitive Landscape And Market Share 2024
- 36.1.1. Top 10 Companies (Ranked by revenue/share)
- 36.2. Long-Acting Injectables (LAIs) Market - Company Scoring Matrix
- 36.2.1. Market Revenues
- 36.2.2. Product Innovation Score
- 36.2.3. Brand Recognition
- 36.3. Long-Acting Injectables (LAIs) Market Company Profiles
- 36.3.1. Johnson And Johnson Overview, Products and Services, Strategy and Financial Analysis
- 36.3.2. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
- 36.3.3. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 36.3.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 36.3.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
37. Long-Acting Injectables (LAIs) Market Other Major And Innovative Companies
- AstraZeneca plc, Sanofi S.A., Novartis AG, Novo Nordisk A/S, GSK plc, Eli Lilly and Company, Bayer AG, Takeda Pharmaceutical Company Limited, Amgen Inc., Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co Ltd., Shionogi And Co Ltd., Dr. Reddy's Laboratories Ltd., ViiV Healthcare, H. Lundbeck A/S, Lupin Limited, Amneal Pharmaceuticals Inc., Alkermes plc, Syngene International Limited
38. Global Long-Acting Injectables (LAIs) Market Competitive Benchmarking And Dashboard
39. Upcoming Startups in the Market
40. Key Mergers And Acquisitions In The Long-Acting Injectables (LAIs) Market
41. Long-Acting Injectables (LAIs) Market High Potential Countries, Segments and Strategies
- 41.1 Long-Acting Injectables (LAIs) Market In 2030 - Countries Offering Most New Opportunities
- 41.2 Long-Acting Injectables (LAIs) Market In 2030 - Segments Offering Most New Opportunities
- 41.3 Long-Acting Injectables (LAIs) Market In 2030 - Growth Strategies
- 41.3.1 Market Trend Based Strategies
- 41.3.2 Competitor Strategies
42. Appendix
- 42.1. Abbreviations
- 42.2. Currencies
- 42.3. Historic And Forecast Inflation Rates
- 42.4. Research Inquiries
- 42.5. The Business Research Company
- 42.6. Copyright And Disclaimer
